Sandoz Group (OTCMKTS:SDZNY) Downgraded by BNP Paribas to Hold

BNP Paribas cut shares of Sandoz Group (OTCMKTS:SDZNY) from a strong-buy rating to a hold rating in a report published on Monday morning,Zacks.com reports.

Separately, Royal Bank of Canada lowered shares of Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, September 16th.

Sandoz Group Stock Down 0.6 %

OTCMKTS SDZNY opened at $43.65 on Monday. The company has a 50-day simple moving average of $44.14 and a 200-day simple moving average of $40.97. Sandoz Group has a one year low of $27.79 and a one year high of $46.80.

Sandoz Group Company Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.